Coherus Biosciences Inc (CHRS)

$2.11

+0.17

(+8.76%)▲

Market is closed - opens 8 PM, 29 Nov 2023

Insights on Coherus Biosciences Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 32.43M → 74.56M (in $), with an average increase of 33.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -74.78M → -39.64M (in $), with an average increase of 41.3% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 76.9% return, outperforming this stock by 146.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 26.8% return, outperforming this stock by 116.4%

Performance

  • $1.85
    $2.15
    $2.11
    downward going graph

    12.56%

    Downside

    Day's Volatility :14.1%

    Upside

    1.76%

    downward going graph
  • $1.43
    $10.99
    $2.11
    downward going graph

    32.23%

    Downside

    52 Weeks Volatility :86.99%

    Upside

    80.8%

    downward going graph

Returns

PeriodCoherus Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-61.58%
-2.6%
0.0%
6 Months
-53.25%
2.2%
0.0%
1 Year
-69.88%
-4.3%
-3.4%
3 Years
-89.49%
19.1%
-4.7%

Highlights

Market Capitalization
225.0M
Book Value
- $1.22
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.55
PEG Ratio
0.0
Wall Street Target Price
11.0
Profit Margin
-102.86%
Operating Margin TTM
-4.57%
Return On Assets TTM
-17.0%
Return On Equity TTM
-1657.06%
Revenue TTM
211.1M
Revenue Per Share TTM
2.46
Quarterly Revenue Growth YOY
64.2%
Gross Profit TTM
-58.4M
EBITDA
-150.5M
Diluted Eps TTM
-2.55
Quarterly Earnings Growth YOY
-0.75
EPS Estimate Current Year
-2.16
EPS Estimate Next Year
-0.11
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.11

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Coherus Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 421.33%

Current $2.11
Target $11.00

Company Financials

FY17Y/Y Change
Revenue
1.6M
↓ 99.18%
Net Income
-238.2M
↑ 87.04%
Net Profit Margin
-15.3K%
↓ 15239.58%
FY18Y/Y Change
Revenue
1.6M
↑ 0.0%
Net Income
-209.3M
↓ 12.11%
Net Profit Margin
-13.5K%
↑ 1852.9%
FY19Y/Y Change
Revenue
356.1M
↑ 22783.74%
Net Income
89.8M
↓ 142.91%
Net Profit Margin
25.23%
↑ 13478.89%
FY20Y/Y Change
Revenue
475.8M
↑ 33.63%
Net Income
132.2M
↑ 47.21%
Net Profit Margin
27.79%
↑ 2.56%
FY21Y/Y Change
Revenue
326.6M
↓ 31.37%
Net Income
-306.3M
↓ 331.63%
Net Profit Margin
-93.81%
↓ 121.6%
FY22Y/Y Change
Revenue
211.0M
↓ 35.37%
Net Income
-326.6M
↑ 6.63%
Net Profit Margin
-154.77%
↓ 60.96%
Q2 FY22Q/Q Change
Revenue
60.2M
↑ 0.06%
Net Income
-56.3M
↓ 49.4%
Net Profit Margin
-93.58%
↑ 91.47%
Q3 FY22Q/Q Change
Revenue
45.4M
↓ 24.48%
Net Income
-92.9M
↑ 64.96%
Net Profit Margin
-204.41%
↓ 110.83%
Q4 FY22Q/Q Change
Revenue
45.4M
↓ 0.16%
Net Income
-66.2M
↓ 28.65%
Net Profit Margin
-146.07%
↑ 58.34%
Q1 FY23Q/Q Change
Revenue
32.4M
↓ 28.48%
Net Income
-74.8M
↑ 12.88%
Net Profit Margin
-230.55%
↓ 84.48%
Q2 FY23Q/Q Change
Revenue
58.7M
↑ 81.02%
Net Income
-42.9M
↓ 42.67%
Net Profit Margin
-73.01%
↑ 157.54%
Q3 FY23Q/Q Change
Revenue
74.6M
↑ 27.0%
Net Income
-39.6M
↓ 7.53%
Net Profit Margin
-53.16%
↑ 19.85%
FY17Y/Y Change
Total Assets
162.6M
↓ 8.89%
Total Liabilities
132.1M
↓ 17.0%
FY18Y/Y Change
Total Assets
99.5M
↓ 38.83%
Total Liabilities
138.1M
↑ 4.53%
FY19Y/Y Change
Total Assets
408.9M
↑ 311.12%
Total Liabilities
303.7M
↑ 119.99%
FY20Y/Y Change
Total Assets
841.6M
↑ 105.82%
Total Liabilities
560.7M
↑ 84.61%
FY21Y/Y Change
Total Assets
679.3M
↓ 19.29%
Total Liabilities
581.6M
↑ 3.73%
FY22Y/Y Change
Total Assets
480.8M
↓ 29.22%
Total Liabilities
618.3M
↑ 6.3%
Q2 FY22Q/Q Change
Total Assets
546.0M
↓ 7.99%
Total Liabilities
568.6M
↓ 2.1%
Q3 FY22Q/Q Change
Total Assets
550.9M
↑ 0.9%
Total Liabilities
648.0M
↑ 13.96%
Q4 FY22Q/Q Change
Total Assets
480.8M
↓ 12.72%
Total Liabilities
618.3M
↓ 4.59%
Q1 FY23Q/Q Change
Total Assets
402.4M
↓ 16.31%
Total Liabilities
598.9M
↓ 3.13%
Q2 FY23Q/Q Change
Total Assets
469.6M
↑ 16.69%
Total Liabilities
644.4M
↑ 7.58%
Q3 FY23Q/Q Change
Total Assets
583.8M
↑ 24.32%
Total Liabilities
717.4M
↑ 11.33%
FY17Y/Y Change
Operating Cash Flow
-200.3M
↓ 20.69%
Investing Cash Flow
-4.4M
↓ 32.2%
Financing Cash Flow
206.8M
↓ 8.57%
FY18Y/Y Change
Operating Cash Flow
-159.3M
↓ 20.48%
Investing Cash Flow
-1.2M
↓ 73.1%
Financing Cash Flow
105.4M
↓ 49.02%
FY19Y/Y Change
Operating Cash Flow
28.4M
↓ 117.8%
Investing Cash Flow
-12.7M
↑ 971.72%
Financing Cash Flow
89.4M
↓ 15.23%
FY20Y/Y Change
Operating Cash Flow
154.1M
↑ 443.63%
Investing Cash Flow
-14.4M
↑ 13.11%
Financing Cash Flow
223.9M
↑ 150.58%
FY21Y/Y Change
Operating Cash Flow
-37.4M
↓ 124.28%
Investing Cash Flow
-138.4M
↑ 861.11%
Financing Cash Flow
51.9M
↓ 76.83%
FY22Y/Y Change
Operating Cash Flow
-241.1M
↑ 544.17%
Investing Cash Flow
-166.9M
↑ 20.55%
Financing Cash Flow
54.3M
↑ 4.72%
Q2 FY22Q/Q Change
Operating Cash Flow
-50.0M
↓ 7.42%
Investing Cash Flow
-880.0K
↓ 97.53%
Financing Cash Flow
721.0K
↓ 138.87%
Q3 FY22Q/Q Change
Operating Cash Flow
-37.1M
↓ 25.88%
Investing Cash Flow
-457.0K
↓ 48.07%
Financing Cash Flow
48.9M
↑ 6677.67%
Q4 FY22Q/Q Change
Operating Cash Flow
-100.0M
↑ 169.49%
Investing Cash Flow
-129.9M
↑ 28324.07%
Financing Cash Flow
6.6M
↓ 86.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-68.7M
↓ 31.24%
Investing Cash Flow
17.5M
↓ 113.49%
Financing Cash Flow
3.8M
↓ 42.3%
Q2 FY23Q/Q Change
Operating Cash Flow
-38.9M
↓ 43.38%
Investing Cash Flow
41.4M
↑ 136.02%
Financing Cash Flow
54.3M
↑ 1328.1%

Technicals Summary

Sell

Neutral

Buy

Coherus Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Coherus Biosciences Inc
Coherus Biosciences Inc
-35.55%
-53.25%
-69.88%
-89.49%
-82.36%
Moderna, Inc.
Moderna, Inc.
4.93%
-38.23%
-55.68%
-49.12%
317.85%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.62%
9.54%
7.63%
54.66%
119.47%
Novo Nordisk A/s
Novo Nordisk A/s
7.75%
29.99%
71.36%
209.46%
351.9%
Seagen, Inc.
Seagen, Inc.
0.13%
10.52%
76.89%
25.9%
249.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.03%
7.65%
11.07%
53.76%
96.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Coherus Biosciences Inc
Coherus Biosciences Inc
NA
NA
0.0
-2.16
-16.57
-0.17
0.0
-1.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.11
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.51
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.76
41.76
2.03
2.65
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.68
26.68
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Coherus Biosciences Inc
Coherus Biosciences Inc
Buy
$225.0M
-82.36%
NA
-102.86%
Moderna, Inc.
Moderna, Inc.
Buy
$29.8B
317.85%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
119.47%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$458.4B
351.9%
41.76
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
249.5%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.4B
96.32%
26.68
35.94%

Institutional Holdings

  • BlackRock Inc

    14.18%

  • Vanguard Group Inc

    8.78%

  • State Street Corporation

    7.89%

  • Temasek Holdings Ltd.

    6.63%

  • Citadel Advisors Llc

    5.37%

  • JPMorgan Chase & Co

    5.14%

Corporate Announcements

  • Coherus Biosciences Inc Earnings

    Coherus Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Organization
Coherus Biosciences Inc
Employees
299
CEO
Mr. Dennis M. Lanfear
Industry
Health Technology

Discover More

FAQs